State health regulators have reviewed 15 private equity healthcare transactions under expanded authority granted after the Steward Health Care bankruptcy, marking the first systematic deployment of post-crisis oversight powers across multiple jurisdictions. The deals, processed without public disclosure requirements in most states, represent the initial test of whether administrative agencies can intercept problematic PE structures before they reach collapse velocity.
The reviews followed Steward's $9 billion May 2024 bankruptcy, which shuttered 31 hospitals across eight states and left $9 billion in liabilities after Cerberus Capital Management extracted sale-leaseback proceeds and management fees. Massachusetts, Texas, and Louisiana regulators obtained emergency authority to examine ownership changes, capital extraction mechanisms, and operator liquidity in pending transactions. The 15 deals under review included hospital acquisitions, ambulatory surgery center roll-ups, and physician practice consolidations—the same asset classes that built Steward's footprint between 2010 and 2020.
The regulatory response matters because it represents the first structural impediment to the $1.1 trillion PE healthcare playbook since ERISA carve-outs enabled pension fund allocations to the sector in the 1990s. State regulators now require disclosure of sale-leaseback structures, management fee schedules, and parent-company debt covenants before transaction approval. Massachusetts specifically demands 36-month liquidity projections and requires PE sponsors to post performance bonds equal to 12 months of operating expenses for hospital transactions. Texas adopted similar bonding requirements in August 2024, applicable to any healthcare facility acquisition exceeding $50 million in enterprise value.
The shift forces PE healthcare operators into a choice: accept the administrative drag of state-by-state compliance, or migrate capital to less-regulated verticals. Early evidence suggests migration. Healthcare PE deal flow dropped 34% in Q3 2024 compared to Q3 2023, according to PitchBook, while PE deployment into healthcare IT and life sciences tools increased 47% over the same period. The regulatory friction creates a two-tier market—legacy portfolios facing exit constraints, and new capital avoiding hard-asset exposure entirely.
Allocators should monitor three developments through Q2 2025: additional state adoptions of the Massachusetts bonding framework, the first transaction denial under the new regimes, and whether federal Medicare regulators extend similar scrutiny to change-of-ownership applications. Massachusetts has 9 pending hospital transactions in the review queue; the first denial would establish case law and appeal timelines that define the practical limits of state authority.
The 15 deals reviewed thus far all received conditional approval, but approval timelines stretched from 45 days to 180 days, adding carrying costs that reduce IRR by 120-340 basis points depending on leverage ratios. That friction, compounded across a portfolio, makes middle-market healthcare services a structurally less attractive deployment target than it was in 2022.